This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Nov 20;320(19):2042.

doi: 10.1001/jama.2018.15938.

Breakthrough Therapy Designation for New Drugs

Edward J Benz Jr¹

Affiliations

PMID: 30458486
DOI: 10.1001/jama.2018.15938

Comment

Breakthrough Therapy Designation for New Drugs

Edward J Benz Jr. JAMA. 2018.

. 2018 Nov 20;320(19):2042.

doi: 10.1001/jama.2018.15938.

Author

Edward J Benz Jr¹

Affiliation

¹ Dana-Farber Cancer Institute, Boston, Massachusetts.

PMID: 30458486
DOI: 10.1001/jama.2018.15938

No abstract available

PubMed Disclaimer

Comment in

Breakthrough Therapy Designation for New Drugs-Reply.
Puthumana J, Wallach JD, Ross JS. Puthumana J, et al. JAMA. 2018 Nov 20;320(19):2042-2043. doi: 10.1001/jama.2018.15942. JAMA. 2018. PMID: 30458490 No abstract available.

Comment on

Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation.
Puthumana J, Wallach JD, Ross JS. Puthumana J, et al. JAMA. 2018 Jul 17;320(3):301-303. doi: 10.1001/jama.2018.7619. JAMA. 2018. PMID: 30027239 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems